The medication is administered via weekly subcutaneous self-injection, with dose titration starting at 0.25 mg weekly and increasing over sixteen to twenty weeks to the target dose of 2.4 mg weekly
For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.trulicity.lilly.com
doi:10.1080/10408398.2017.1357534
Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM
It should be noted that the staining intensity was also higher in the PDL9 group
What distinguishes ipamorelin from earlier GHS compounds (such as GHRP-6 and GHRP-2) is its remarkable selectivity